查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1595126

卵巢癌診斷市場：按癌症類型、診斷類型和最終用戶分類 - 全球預測 2025-2030

Ovarian Cancer Diagnostics Market by Cancer Type (Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor), Diagnosis Type (Biopsy, Blood Test, Imaging), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年卵巢癌診斷市場價值為71.7億美元，預計到2024年將達到81.8億美元，複合年成長率為14.50%，到2030年將達到185億美元。

卵巢癌診斷市場的範圍和定義包括用於卵巢癌早期檢測、診斷和監測的各種測試和技術。由於卵巢癌通常在晚期才被發現，因此改進診斷方法對於提高患者存活率至關重要。這些診斷的應用擴展到醫院、實驗室和診所，最終用戶包括醫療保健相關人員、研究人員和易患卵巢癌的個人。影響市場成長的主要因素包括卵巢癌盛行率的上升、液態切片和診斷成像技術等診斷技術的進步以及對癌症早期檢測的認知不斷提高。此外，政府對癌症研究的措施和資助也有助於市場擴張。開發非侵入性診斷工具、增強生物標記識別以及整合人工智慧以提高診斷準確性存在機會。這些可能會鼓勵製藥公司和研究機構的技術創新。

主要市場統計
基準年[2023] 71.7億美元
預測年份 [2024] 81.8億美元
預測年份 [2030] 185億美元
複合年成長率（%） 14.50%

然而，準確診斷面臨重大挑戰，包括診斷成本高、低收入地區的可用性有限以及卵巢癌病理學的複雜性。此外，嚴格的監管政策可能會推遲新診斷工具的核准。為了克服這些挑戰，公司應該專注於具有成本效益和擴充性的診斷解決方案，特別是對於服務不足的市場。最佳創新領域是開發結合成像、生物標記和基因檢測的多模態診斷方法。此外，用於連續監測的穿戴式技術的發展有可能徹底改變早期診斷工作。總體而言，該市場是一個充滿活力的市場，具有高成長潛力，受到技術進步和對精確診斷不斷成長的需求的推動，但受到成本、可及性和監管障礙的限制。尋求發展的公司應優先考慮研發方面的合作和夥伴關係，並專注於開發人工智慧主導的診斷技術，以提高市場滲透率和患者治療效果。

市場動態：快速發展的卵巢癌診斷市場的關鍵市場洞察

供需的動態交互作用正在改變卵巢癌診斷市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 增加政府對卵巢癌研究的承諾和資助
    • 全球女性卵巢癌盛行率不斷上升
    • 早期診斷和治療的潛在需求
  • 市場限制因素
    • 診斷費用相對較高，人們擔心治療的副作用。
  • 市場機會
    • 現代化的興起和卵巢癌診斷工具的進步
    • 繼續應用聯合治療治療卵巢癌
  • 市場挑戰
    • 對卵巢癌的認知降低且缺乏準確診斷

波特五力：開拓卵巢癌診斷市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解卵巢癌診斷市場的外部影響

外部宏觀環境因素在塑造卵巢癌診斷市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解卵巢癌診斷藥物市場的競爭狀況

卵巢癌診斷市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣卵巢癌診斷市場供應商績效評估

FPNV定位矩陣是評估卵巢癌診斷市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了卵巢癌診斷市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對卵巢癌診斷市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告提供了涵蓋關鍵重點領域的市場全面分析：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 政府對卵巢癌研究的積極承諾和增加資金
      • 全球女性卵巢癌發生率呈上升趨勢
      • 早期診斷和治療的潛在需求
    • 抑制因素
      • 診斷費用相對較高，且患者擔心治療副作用。
    • 機會
      • 卵巢癌診斷技術的現代化與進步
      • 聯合治療在卵巢癌治療的持續應用
    • 任務
      • 對卵巢癌的認知下降和缺乏準確診斷
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章按癌症類型分類的卵巢癌診斷藥物市場

  • 上皮性腫瘤
  • 生殖細胞腫瘤
  • 間質細胞瘤

第7章依診斷類型分類的卵巢癌診斷藥物市場

  • 切片檢查
  • 驗血
    • BRCA
    • CA125
    • 印度核能管理局
    • 急診室及公關
    • HER2
    • KRAS突變
  • 影像
    • 電腦斷層掃描
    • 核磁共振掃描
    • 正子斷層掃描
    • 超音波

第8章卵巢癌診斷市場：依最終用戶分類

  • 癌症診斷中心
  • 醫院實驗室
  • 調查機構

第9章北美和南美卵巢癌診斷藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區卵巢癌診斷市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲的卵巢癌診斷市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories Ltd.
  • Almac Group
  • Apollo Diagnostics
  • AstraZeneca PLC
  • Avalon Health Economics LLC
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Laboratory Corporation of America Holdings
  • MedGenome Labs Ltd.
  • Myriad Genetics Inc.
  • Oncgnostics GmbH
  • Ovation Diagnostics LLC
  • Pfizer, Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-ED54C46E9279

The Ovarian Cancer Diagnostics Market was valued at USD 7.17 billion in 2023, expected to reach USD 8.18 billion in 2024, and is projected to grow at a CAGR of 14.50%, to USD 18.50 billion by 2030.

The scope and definition of the ovarian cancer diagnostics market encompass a range of tests and technologies employed for the early detection, diagnosis, and monitoring of ovarian cancer. As ovarian cancer is often detected in advanced stages, the necessity for improved diagnostics is critical to enhance patient survival rates. The application of these diagnostics extends to hospitals, research labs, and clinics, while end-users include medical professionals, researchers, and individuals with a predisposition to ovarian cancer. Key factors influencing market growth include the rising prevalence of ovarian cancer, advancements in diagnostic technologies like liquid biopsies and imaging techniques, and increased awareness about early cancer detection. Additionally, government initiatives and funding aimed at cancer research contribute to market expansion. Opportunities lie in the development of non-invasive diagnostic tools, enhanced biomarker identification, and the integration of artificial intelligence to improve diagnostic accuracy. These will encourage pharmaceutical companies and research institutions to innovate.

KEY MARKET STATISTICS
Base Year [2023] USD 7.17 billion
Estimated Year [2024] USD 8.18 billion
Forecast Year [2030] USD 18.50 billion
CAGR (%) 14.50%

However, there are significant challenges such as high costs of diagnostic procedures, limited availability in low-income regions, and the complexity of ovarian cancer pathology which can impede accurate diagnosis. Moreover, stringent regulatory policies can slow down the approval of novel diagnostic tools. To overcome these challenges, companies should focus on cost-effective and scalable diagnostic solutions, particularly for underserved markets. The best areas of innovation include the development of multi-modal diagnostic approaches that combine imaging, biomarkers, and genetic testing. Furthermore, developing wearable technology for continuous monitoring could revolutionize early diagnosis efforts. Overall, the market is dynamic with high growth potential, driven by technological advancements and increasing demand for precise diagnostics, yet it is limited by cost, accessibility, and regulatory hurdles. Companies aiming for growth should prioritize collaborations and partnerships for research and development, and focus on developing AI-driven diagnostics to enhance market penetration and patient outcomes.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Ovarian Cancer Diagnostics Market

The Ovarian Cancer Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing favorable government initiatives and growing funding for ovarian cancer research
    • Growing prevalence of ovarian cancer among women worldwide
    • Potential demand for early diagnosis and treatment
  • Market Restraints
    • Relatively high cost of diagnosis and concerns of adverse effects of the treatment among patients
  • Market Opportunities
    • Emerging modernization and advancements in technical diagnostic tools for ovarian cancer
    • Ongoing application of combination therapies to treat ovarian cancer
  • Market Challenges
    • Reduced awareness and dearth of precise diagnosis of ovarian cancer

Porter's Five Forces: A Strategic Tool for Navigating the Ovarian Cancer Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Ovarian Cancer Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Ovarian Cancer Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Ovarian Cancer Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Ovarian Cancer Diagnostics Market

A detailed market share analysis in the Ovarian Cancer Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Ovarian Cancer Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Ovarian Cancer Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Ovarian Cancer Diagnostics Market

A strategic analysis of the Ovarian Cancer Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Ovarian Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories Ltd., Almac Group, Apollo Diagnostics, AstraZeneca PLC, Avalon Health Economics LLC, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Laboratory Corporation of America Holdings, MedGenome Labs Ltd., Myriad Genetics Inc., Oncgnostics GmbH, Ovation Diagnostics LLC, Pfizer, Inc., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Ovarian Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Cancer Type, market is studied across Epithelial Tumor, Germ Cell Tumor, and Stromal Cell Tumor.
  • Based on Diagnosis Type, market is studied across Biopsy, Blood Test, and Imaging. The Blood Test is further studied across BRCA, CA125, CEA, ER & PR, HER2, and KRAS Mutation. The Imaging is further studied across CT Scan, MRI Scan, PET Scan, and Ultrasound.
  • Based on End-User, market is studied across Cancer Diagnostic Centers, Hospital Laboratories, and Research Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing favorable government initiatives and growing funding for ovarian cancer research
      • 5.1.1.2. Growing prevalence of ovarian cancer among women worldwide
      • 5.1.1.3. Potential demand for early diagnosis and treatment
    • 5.1.2. Restraints
      • 5.1.2.1. Relatively high cost of diagnosis and concerns of adverse effects of the treatment among patients
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging modernization and advancements in technical diagnostic tools for ovarian cancer
      • 5.1.3.2. Ongoing application of combination therapies to treat ovarian cancer
    • 5.1.4. Challenges
      • 5.1.4.1. Reduced awareness and dearth of precise diagnosis of ovarian cancer
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Ovarian Cancer Diagnostics Market, by Cancer Type

  • 6.1. Introduction
  • 6.2. Epithelial Tumor
  • 6.3. Germ Cell Tumor
  • 6.4. Stromal Cell Tumor

7. Ovarian Cancer Diagnostics Market, by Diagnosis Type

  • 7.1. Introduction
  • 7.2. Biopsy
  • 7.3. Blood Test
    • 7.3.1. BRCA
    • 7.3.2. CA125
    • 7.3.3. CEA
    • 7.3.4. ER & PR
    • 7.3.5. HER2
    • 7.3.6. KRAS Mutation
  • 7.4. Imaging
    • 7.4.1. CT Scan
    • 7.4.2. MRI Scan
    • 7.4.3. PET Scan
    • 7.4.4. Ultrasound

8. Ovarian Cancer Diagnostics Market, by End-User

  • 8.1. Introduction
  • 8.2. Cancer Diagnostic Centers
  • 8.3. Hospital Laboratories
  • 8.4. Research Institutes

9. Americas Ovarian Cancer Diagnostics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Ovarian Cancer Diagnostics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Ovarian Cancer Diagnostics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories Ltd.
  • 2. Almac Group
  • 3. Apollo Diagnostics
  • 4. AstraZeneca PLC
  • 5. Avalon Health Economics LLC
  • 6. Becton, Dickinson and Company
  • 7. Bio-Rad Laboratories, Inc.
  • 8. F. Hoffmann-La Roche AG
  • 9. GlaxoSmithKline PLC
  • 10. Laboratory Corporation of America Holdings
  • 11. MedGenome Labs Ltd.
  • 12. Myriad Genetics Inc.
  • 13. Oncgnostics GmbH
  • 14. Ovation Diagnostics LLC
  • 15. Pfizer, Inc.
  • 16. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. OVARIAN CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. OVARIAN CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. OVARIAN CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. OVARIAN CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. OVARIAN CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. OVARIAN CANCER DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY EPITHELIAL TUMOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY GERM CELL TUMOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY STROMAL CELL TUMOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BRCA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CA125, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CEA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY ER & PR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY HER2, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY KRAS MUTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY MRI SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY PET SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 240. OVARIAN CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 241. OVARIAN CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023